- Home
- OPK vs PCRX Comparison
OPK vs PCRX Comparison
Compare OPK & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPK
- PCRX
- Stock Information
- Founded
- OPK 2007
- PCRX 2006
- Country
- OPK United States
- PCRX United States
- Employees
- OPK N/A
- PCRX N/A
- Industry
- OPK Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- OPK Health Care
- PCRX Health Care
- Exchange
- OPK Nasdaq
- PCRX Nasdaq
- Market Cap
- OPK 1.1B
- PCRX 1.2B
- IPO Year
- OPK 1995
- PCRX 2011
- Fundamental
- Price
- OPK $1.19
- PCRX $22.07
- Analyst Decision
- OPK Buy
- PCRX Buy
- Analyst Count
- OPK 4
- PCRX 8
- Target Price
- OPK $2.75
- PCRX $28.38
- AVG Volume (30 Days)
- OPK 2.8M
- PCRX 550.1K
- Earning Date
- OPK 07-31-2025
- PCRX 08-05-2025
- Dividend Yield
- OPK N/A
- PCRX N/A
- EPS Growth
- OPK N/A
- PCRX N/A
- EPS
- OPK N/A
- PCRX N/A
- Revenue
- OPK $664,029,000.00
- PCRX $702,772,000.00
- Revenue This Year
- OPK N/A
- PCRX $7.90
- Revenue Next Year
- OPK $6.98
- PCRX $11.02
- P/E Ratio
- OPK N/A
- PCRX N/A
- Revenue Growth
- OPK N/A
- PCRX 3.08
- 52 Week Low
- OPK $1.11
- PCRX $11.16
- 52 Week High
- OPK $2.04
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- OPK 29.73
- PCRX 44.39
- Support Level
- OPK $1.34
- PCRX $20.85
- Resistance Level
- OPK $1.38
- PCRX $22.32
- Average True Range (ATR)
- OPK 0.06
- PCRX 0.84
- MACD
- OPK -0.02
- PCRX 0.01
- Stochastic Oscillator
- OPK 23.53
- PCRX 44.69
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.